dc.contributor.author
Muñoz Pujol, Gerard
dc.contributor.author
Ortigoza Escobar, Juan D.
dc.contributor.author
Paredes Fuentes, Abraham José
dc.contributor.author
Jou, Cristina
dc.contributor.author
Ugarteburu López, Olatz
dc.contributor.author
Gort, Laura
dc.contributor.author
Yubero, Delia
dc.contributor.author
Garcia Cazorla, Angels
dc.contributor.author
O'Callaghan, Mar
dc.contributor.author
Campistol Plana, Jaume
dc.contributor.author
Muchart, Jordi.
dc.contributor.author
Yépez, Vicente A.
dc.contributor.author
Gusic, Mirjana
dc.contributor.author
Gagneur, Julien
dc.contributor.author
Prokisch, Holger
dc.contributor.author
Artuch Iriberri, Rafael
dc.contributor.author
Ribes Rubió, Maria Antònia
dc.contributor.author
Urreizti, Roser
dc.contributor.author
Tort, Frederic
dc.date.issued
2024-02-19T07:52:58Z
dc.date.issued
2024-02-19T07:52:58Z
dc.date.issued
2022-11-30
dc.date.issued
2024-02-13T13:52:10Z
dc.identifier
https://hdl.handle.net/2445/207740
dc.description.abstract
Mitochondrial translation defects are a continuously growing group of disorders showing a large variety of clinical symptoms including a wide range of neurological abnormalities. To date, mutations in PTCD3, encoding a component of the mitochondrial ribosome, have only been reported in a single individual with clinical evidence of Leigh syndrome. Here, we describe three additional PTCD3 individuals from two unrelated families, broadening the genetic and phenotypic spectrum of this disorder, and provide definitive evidence that PTCD3 deficiency is associated with Leigh syndrome. The patients presented in the first months of life with psychomotor delay, respiratory insufficiency and feeding difficulties. The neurologic phenotype included dystonia, optic atrophy, nystagmus and tonic-clonic seizures. Brain MRI showed optic nerve atrophy and thalamic changes, consistent with Leigh syndrome. WES and RNA-seq identified compound heterozygous variants in PTCD3 in both families: c.[1453-1G>C];[1918C>G] and c.[710del];[902C>T]. The functional consequences of the identified variants were determined by a comprehensive characterization of the mitochondrial function. PTCD3 protein levels were significantly reduced in patient fibroblasts and, consistent with a mitochondrial translation defect, a severe reduction in the steady state levels of complexes I and IV subunits was detected. Accordingly, the activity of these complexes was also low, and high-resolution respirometry showed a significant decrease in the mitochondrial respiratory capacity. Functional complementation studies demonstrated the pathogenic effect of the identified variants since the expression of wild-type PTCD3 in immortalized fibroblasts restored the steady-state levels of complexes I and IV subunits as well as the mitochondrial respiratory capacity. Additionally, minigene assays demonstrated that three of the identified variants were pathogenic by altering PTCD3 mRNA processing. The fourth variant was a frameshift leading to a truncated protein. In summary, we provide evidence of PTCD3 involvement in human disease confirming that PTCD3 deficiency is definitively associated with Leigh syndrome.© 2022 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology.
dc.format
application/pdf
dc.publisher
John Wiley & Sons, Inc
dc.relation
Reproducció del document publicat a: https://doi.org/10.1111/bpa.13134
dc.relation
Brain Pathology, 2023, vol. 33, num. 3, p. e13134-NA
dc.relation
https://doi.org/10.1111/bpa.13134
dc.rights
cc by-nc-nd (c) Muñoz, Pujol G. et al., 2022
dc.rights
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
dc.subject
Mutació (Biologia)
dc.subject
Mutation (Biology)
dc.title
Leigh syndrome is the main clinical characteristic of PTCD3 deficiency
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion